Android app Apple app link

H.C. Wainwright Reiterates a Buy Rating on Vertex Pharmaceuticals (VRTX)

By Yahoo! Finance   |   1 month ago
H.C. Wainwright Reiterates a Buy Rating on Vertex Pharmaceuticals (VRTX)

Vertex Pharmaceuticals (NASDAQ:VRTX) is a top biotech stock with a Buy rating and $478 price target. Analyst sees potential in kidney franchise and innovative treatments for diseases like membranous nephropathy. Company develops medicines for rare diseases like cystic fibrosis and sickle cell disease.

Read More

Did you find this insightful?

Exclusive Content

Access to this content is reserved for premium members. Unlock all features by upgrading to a premium membership.

Get the App

To join as a premium member, please download our app and complete your membership purchase there.